Welcome

Renovo is a biopharmaceutical product company and is a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue registration.

The Board are pleased to announce that all resoltions placed before the General Meeting held on 12 September 2011 were duly passed. Further details may be viewed here.

An indexed pdf version of our 2011 Annual Report is now available in our Investors' section.

Renovo Business Strategy

Renovo is well funded and its future strategy is aimed at maximising shareholder value. The Company will consider all options available to it which may include acquisitions and mergers of external companies in addition to realising value where possible from its current portfolio of clinical and preclinical candidates and intellectual property. The directors do not intend to place any restrictions on the nature of the business carried out by potential acquisition and merger targets. Renovo’s cost base is being minimised wherever possible in order to maximise the Company’s available cash.

News, Events and Announcements

No events for this year.

Renovo Group: Brooke to succeed Ferguson as chairman

Monday, 9 January 2012

Renovo Group (LON:RNVO) told investors that non-executive director Jamie Brooke will succeed Professor Mark WJ Ferguson as chairman of the company on January 15 this year.

Professor...Read more

Renovo Group to start share buy-back

Thursday, 15 December 2011

Renovo Group (LON:RNVO) said it will now start the share buy-back that was announced in August 2011 and approved by shareholders at the AGM in September.
Read more